Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice.

Peroxisome proliferators (PPs) are a large class of structurally diverse chemicals, which includes drugs designed to improve the metabolic abnormalities linking hypertriglyceridemia to diabetes, hyperglycemia, insulin-resistance and atherosclerosis. We have recently demonstrated that exposure of rodents to potent PPs indirectly causes a number of immunomodulating effects, resulting in severe adaptive immunosuppression. Since the peroxisome proliferator-activated receptor alpha (PPARalpha) plays a central role in mediating the pleiotropic responses exerted by PPs, we have compared here the immunomodulating effects of the PPs perfluorooctanoic acid (PFOA) and Wy-14,643 in wild-type and PPARalpha-null mice. The reductions in spleen weight and in the number of splenocytes caused by PP treatment in wild-type mice was not observed in PPARalpha-null mice. Furthermore, the reductions in thymus weight and in the number of thymocytes were potently attenuated in the latter animals. Similarly, the dramatic decreases in the size of the CD4(+)CD8(+) population of cells in the thymus and in the number of thymocytes in the S and G2/M phases of the cell cycle observed in wild-type mice administered PPs were much less extensive in PPARalpha-null mice. Finally, in contrast to the case of wild-type animals, the response of splenocytes isolated from the spleen of PP-treated PPARalpha-null mice to appropriate T- or B-cell activators in vitro was not reduced. Altogether, these data indicate that PPARalpha plays a major role in the immunomodulation caused by PPs. The possible relevance of these changes to the alterations in plasma lipids also caused by PPs is discussed.

[1]  J. Descotes An introduction to immunotoxicology , 1998 .

[2]  T. Nishimaki-Mogami,et al.  Perfluorooctanoic acid, a peroxisome-proliferating hypolipidemic agent, dissociates apolipoprotein B48 from lipoprotein particles and decreases secretion of very low density lipoproteins by cultured rat hepatocytes. , 1999, Biochimica et biophysica acta.

[3]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[4]  R. G. Anderson The caveolae membrane system. , 1998, Annual review of biochemistry.

[5]  B. Lake Peroxisome proliferation: current mechanisms relating to nongenotoxic carcinogenesis. , 1995, Toxicology letters.

[6]  J. V. Vanden Heuvel,et al.  Disposition of perfluorodecanoic acid in male and female rats. , 1991, Toxicology and applied pharmacology.

[7]  C. Janeway Immunobiology: The Immune System in Health and Disease , 1996 .

[8]  Michel Fournier,et al.  Immunotoxicity of pesticides: a review , 1999, Toxicology and industrial health.

[9]  V. Herzberg Human T lymphocytes require lipid as either lipoprotein or nonesterified fatty acid for in vitro activation. , 1991, Immunological investigations.

[10]  Newsholme Ea,et al.  Metabolism in lymphocytes and its importance in the immune response. , 1985 .

[11]  J. Depierre,et al.  Effects of peroxisome proliferators on the thymus and spleen of mice , 2000, Clinical and experimental immunology.

[12]  W. Wahli,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding , 2022 .

[13]  P. Lipsky,et al.  Promotion of human T lymphocyte activation and proliferation by fatty acids in low density and high density lipoproteins. , 1986, The Journal of biological chemistry.

[14]  Qiang Yang,et al.  Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. , 2001, Biochemical pharmacology.

[15]  G. Hansson Cell-mediated immunity in atherosclerosis , 1997, Current opinion in lipidology.

[16]  Russell K Yamazaki,et al.  Determination of peroxisomal fatty acyl-CoA oxidase activity using a lauroyl-CoA-based fluorometric assay. , 1986, Biochimica et biophysica acta.

[17]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[18]  J. Witztum,et al.  T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Cottier,et al.  The Role of Cholesterol and Its Biosynthesis in Lymphocyte Proliferation and Differentiation a , 1985, Annals of the New York Academy of Sciences.

[20]  G. Möller,et al.  In vitro effects of HgCl2 on murine lymphocytes. I. Preferable activation of CD4+ T cells in a responder strain. , 1995, Journal of immunology.

[21]  J. Auwerx,et al.  Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. , 1996, Atherosclerosis.

[22]  R. Murphy,et al.  Effect of peroxisome proliferator-activated receptor alpha activation on leukotriene B4 metabolism in isolated rat hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.

[23]  Qian Yang,et al.  Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. , 2002, International immunopharmacology.

[24]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[25]  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[26]  J. Corton,et al.  Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. , 2000, Annual review of pharmacology and toxicology.

[27]  P. Lipsky,et al.  Lipoproteins may provide fatty acids necessary for human lymphocyte proliferation by both low density lipoprotein receptor-dependent and -independent mechanisms. , 1989, The Journal of biological chemistry.

[28]  J M Ward,et al.  Receptor and Nonreceptor-Mediated Organ-Specific Toxicity of Di(2-ethylhexyl)phthalate (DEHP) in Peroxisome Proliferator-Activated Receptorα-Null Mice , 1998, Toxicologic pathology.

[29]  G. Rosenthal,et al.  Chemical agents and the immune response. , 1993, Environmental health perspectives.

[30]  J. Depierre,et al.  Perfluorooctanoic acid has persistent effects on peroxisome proliferation and related parameters in mouse liver. , 1992, Journal of biochemical toxicology.

[31]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[32]  B. Seed,et al.  Membrane compartmentation and the response to antigen. , 1999, Current opinion in immunology.

[33]  R. Roberts Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences , 1999, Archives of Toxicology.

[34]  M Tanaka,et al.  The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. , 1985, Journal of biochemistry.

[35]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[36]  J. Peters,et al.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.

[37]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[38]  J. Peters,et al.  Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.

[39]  W. Stoffel,et al.  Perturbation of membrane microdomains reduces mitogenic signaling and increases susceptibility to apoptosis after T cell receptor stimulation , 2000, Cell Death and Differentiation.